Remove Botox Remove Marketing Remove Sales Remove Trials
article thumbnail

AbbVie’s Qulipta cleared for migraine prevention, setting up Biohaven clash

pharmaphorum

AbbVie has added a third drug to its arsenal in the crowded migraine market, getting FDA approval for Qulipta – its once-daily oral preventive therapy for episodic migraines. AbbVie acquired Qulipta in 2020 as part of its $63 billion takeover of Allergan, which also brought in Botox and Ubrelvy.

Botox 52
article thumbnail

Novartis’ Aimovig tops topiramate in migraine face-off

pharmaphorum

Novartis’ injectable migraine prevention antibody Aimovig has been shown to be more effective than topiramate – a go-to oral therapy for people with chronic migraine – in a head-to-head trial. The company has exclusive rights to the sell Aimovig outside the US, where Amgen records sales, with the exception of Japan.

Botox 96
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

NICE backs Lilly’s Emgality for migraine, adding pressure on Novartis

pharmaphorum

The decision means that with two CGRP antibodies now cleared for migraine prevention, the first drug in the class to be approved in Europe – Novartis’ Aimovig (erenumab) – has fallen further behind its rivals in getting access to the UK market.

Sales 96
article thumbnail

NICE backs Lilly’s Emgality for migraine, adding pressure on Novartis

pharmaphorum

The decision means that with two CGRP antibodies now cleared for migraine prevention, the first drug in the class to be approved in Europe – Novartis’ Aimovig (erenumab) – has fallen further behind its rivals in getting access to the UK market.

Sales 94
article thumbnail

Latest ABPI code breaches reveal the risk of ‘likes’ on LinkedIn

pharmaphorum

Allergan fell foul of the regulations for a number of LinkedIn and Instagram posts promoting Botox (botulinum toxin type A) to the public by the chief executive of aesthetics clinic – described in his profile as an ‘Allergan mentee’, which were also liked or commented on by employees of the company.

Botox 64
article thumbnail

Top 30 Pharma and Biotech Companies in 2023: Statistics and Trends

XTalks

Join us as we present an in-depth analysis of each company’s revenue, net income, R&D investments, core therapeutic areas, market presence and strategic collaborations. is a global pharmaceutical company, working across both developed and emerging markets. billion in pharmaceutical sales from 2021. billion, a 42.74

Sales 98
article thumbnail

AbbVie Reports Second-Quarter 2021 Financial Results

The Pharma Data

AbbVie delivered another strong quarter and our business continues to perform extremely well across the portfolio, with AbbVie’s new immunology assets contributing more than $1 billion of combined sales in the quarter,” said Richard A. Global Botox Therapeutic net revenues were $603 million, an increase of over 100.0

Botox 52